ArticleScientific reports2024
Enhancing astaxanthin biosynthesis and pathway expansion towards glycosylated C40 carotenoids by Corynebacterium glutamicum.
Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.
- Exploring the benefits of astaxanthin as a functional food ingredient: Its effects on oxidative stress and reproductive outcomes in women with PCOS - A systematic review and single-arm meta-analysis of randomized clinical trials.Naunyn-Schmiedeberg's archives of pharmacology · 2025Pooled it
- Metabolic engineering of endogenous MEP pathway for enhanced lycopene production inSynthetic and systems biotechnology · 2026Article
- Superior Intracellular Antioxidant Activity of an Astaxanthin-Containing Corynebacterial Extract.International journal of molecular sciences · 2026Article
- Pathway reconstruction of Corynebacterium glutamicum for C30 carotenoid 4,4'-diaponeurosporene production.Journal of biological engineering · 2026Article
- Heterologous Production of 2,2'-Dihydroxy Derivatives of Astaxanthin and Adonirubin inAntioxidants (Basel, Switzerland) · 2026Article
- Harnessing synthetic biology for tetraterpenoid astaxanthin production: Recent advances and challenges.Synthetic and systems biotechnology · 2026Review
- Design and validation of an inducible and curable EvolvR system for directed evolution inFrontiers in bioengineering and biotechnology · 2026Article
- Sustainable Natural Product Glycosylation: A Critical Evaluation of Biocatalytic and Chemical Approaches.ChemSusChem · 2025Review
- Supercritical carbon dioxide extraction of astaxanthin from Corynebacterium glutamicum.Bioresources and bioprocessing · 2025Article
- Biosynthesis of Edible Terpenoids: Hosts and Applications.Foods (Basel, Switzerland) · 2025Review
- Review
- Response surface-based media optimization for astaxanthin production inFrontiers in bioengineering and biotechnology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Astaxanthin, a versatile C40 carotenoid prized for its applications in food, cosmetics, and health, is a bright red pigment with powerful antioxidant properties. To enhance astaxanthin production in Corynebacterium glutamicum, we employed rational pathway engineering strategies, focused on improving precursor availability and optimizing terminal oxy-functionalized C40 carotenoid biosynthesis. Our efforts resulted in an increased astaxanthin precursor supply with 1.5-fold higher β-carotene production with strain BETA6 (18 mg g
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.